PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.83
AASLD 2020,
“SELECTIVE ESTROGEN RECEPTOR MODULATOR, OSU-ERB-12, AMELIORATES PRECLINICAL MODELS OF HEPATIC FIBROSIS AND NASH.” Ohio State University
No.82
AASLD 2020,
“PRECLINICAL DEVELOPMENT OF SMALL MOLECULE DRUG DISCOVERY LEADS WITH NOVEL MOAS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH)” Twoxar
No.81
AASLD 2020,
“IRON LOSS TRIGGERS MITOPHAGY THROUGH INDUCTION OF MITOCHONDRIAL FERRITIN” Kawasaki Medicel School
No.80
EASL the International Liver CongressTM 2020,
“Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma” Kawasaki Medical School
No.79
EASL the International Liver CongressTM 2020,
“GPNMB modulates hepatic steatogenesis and liver cancer” Heidelberg University
No.78
EASL the International Liver CongressTM 2020,
“2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity” Kawasaki Medical School
No.77
EASL the International Liver CongressTM 2020,
“Novel autophagy inducer, a4368 improves non-alchoholic steatohepatitis in mice” Autophagy Sciences.
No.76
EASL the International Liver CongressTM 2020,
“Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis” OncoArendi Therapeutics SA.
No.75
EASL the International Liver CongressTM 2020,
“A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers” Future Medicine Co., Ltd.
No.74
DDW 2020,
"NON-ALCOHOLIC STEATOHEPATITIS-ASSOCIATED ALTERATION OF INFLAMMATORY LIPID MEDIATORS, PRIMARY METABOLITES AND MICROBIOME IN A STAM MOUSE MODEL, AND THERAPEUTIC POTENTIAL OF A JAPANESE TRADITIONAL MEDICINE, DAISAIKOTO” TSUMURA & Co.